Back to Browse Journals » Vascular Health and Risk Management » Volume 9

Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment

Authors Lukashevich V, Schweizer A, Foley JE, Dickinson S, Groop PH, Kothny W

Published Date January 2013 Volume 2013:9 Pages 21—28

DOI http://dx.doi.org/10.2147/VHRM.S39300

Received 18 October 2012, Accepted 26 November 2012, Published 23 January 2013

Valentina Lukashevich,1 Anja Schweizer,2 James E Foley,1 Sheila Dickinson,2 Per-Henrik Groop,3 Wolfgang Kothny1

1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 2Novartis Pharma AG, Basel, Switzerland; 3Division of Nephrology, Department of Medicine, Helsinki University Central Hospital, Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Finland, and Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia

Background: The purpose of this study was to evaluate the efficacy of vildagliptin 50 mg once daily in patients with severe renal impairment (estimated glomerular filtration rate < 30 mL/min/1.73 m2) and longstanding type 2 diabetes not adequately controlled with insulin therapy, which is a difficult-to-treat population, with limited therapeutic options and a high susceptibility to hypoglycemia.
Methods: This was a post hoc subanalysis of data obtained during a previously described randomized, double-blind, parallel-group, 24-week study comparing the efficacy and safety of vildagliptin 50 mg once daily versus placebo in patients with type 2 diabetes and moderate or severe renal impairment. The present data derive from 178 patients with severe renal impairment (baseline estimated glomerular filtration rate approximately 21 mL/min/1.73 m2, 100 randomized to vildagliptin, 78 randomized to placebo), all of whom were receiving insulin therapy (alone or in combination with an oral antidiabetic agent) for longstanding type 2 diabetes (mean approximately 19 years).
Results: With vildagliptin in combination with insulin, the adjusted mean change (AMΔ) in HbA1c from baseline (7.7% ± 0.1%) was -0.9% ± 0.4% and the between-treatment difference (vildagliptin – placebo) was -0.6% ± 0.2% (P < 0.001). The percentage of patients achieving endpoint HbA1c < 7.0% was significantly higher with vildagliptin than placebo (45.2% versus 22.8%, P = 0.008). When added to insulin, vildagliptin and placebo had comparable hypoglycemic profiles and did not cause weight gain. Both treatments were similarly well tolerated, with comparable incidences of adverse events, serious adverse events, and deaths.
Conclusion: When added to insulin therapy in patients with severe renal impairment and longstanding type 2 diabetes, vildagliptin 50 mg once daily was efficacious, eliciting HbA1c reductions consistent with those previously reported for a patient population with much more recent onset of type 2 diabetes and normal renal function, and had a hypoglycemic profile comparable with placebo. Accordingly, vildagliptin is a suitable treatment option for patients with advanced type 2 diabetes and impaired renal function who require insulin therapy and present a serious therapeutic challenge in clinical practice.

Keywords: chronic kidney disease, antidiabetic drug, dipeptidyl peptidase-4 inhibitor, glucagon-like peptide-1, type 2 diabetes

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Ageism and its clinical impact in oncogeriatry: state of knowledge and therapeutic leads

Schroyen S, Adam S, Jerusalem G, Missotten P

Clinical Interventions in Aging 2015, 10:117-125

Published Date: 31 December 2014

Evaluation of the iPad as a low vision aid for improving reading ability

Haji SA, Sambhav K, Grover S, Chalam KV

Clinical Ophthalmology 2015, 9:17-20

Published Date: 19 December 2014

Parkinson’s disease-associated melanin steal

Hinz M, Stein A, Cole T

Neuropsychiatric Disease and Treatment 2014, 10:2331-2337

Published Date: 10 December 2014

Effects of different doses of testosterone on gonadotropins, 25-hydroxyvitamin D3, and blood lipids in healthy men

Gårevik N, Rane A, Björkhem-Bergman L, Ekström L

Substance Abuse and Rehabilitation 2014, 5:121-127

Published Date: 10 December 2014

Experience of insomnia, symptom attribution and treatment preferences in individuals with moderate to severe COPD: a qualitative study

Kauffman KS, Doede M, Diaz-Abad M, Scharf SM, Bell-Farrell W, Rogers VE, Geiger-Brown J

Patient Preference and Adherence 2014, 8:1699-1704

Published Date: 10 December 2014

Acute-on-chronic liver failure: a review

Zamora Nava LE, Aguirre Valadez J, Chávez-Tapia NC, Torre A

Therapeutics and Clinical Risk Management 2014, 10:295-303

Published Date: 23 April 2014

Molecular network topology and reliability for multipurpose diagnosis

Jalil MA, Moongfangklang N, Innate K, Mitatha S, Ali J, Yupapin PP

International Journal of Nanomedicine 2011, 6:2385-2392

Published Date: 19 October 2011

Corrigendum: Softec HD hydrophilic acrylic intraocular lens: biocompatibility and precision

Espandar L, Sikder S, Moshirfar M

Clinical Ophthalmology 2011, 5:159-160

Published Date: 6 February 2011

Differential effects of nanoselenium doping on healthy and cancerous osteoblasts in coculture on titanium

Phong A Tran, Love Sarin, Robert H Hurt, et al

International Journal of Nanomedicine 2010, 5:351-358

Published Date: 10 May 2010

Corneal abrasion

Scott Fraser

Clinical Ophthalmology 2010, 4:387-390

Published Date: 26 April 2010